Integra LifeSciences Announces Key Executive Appointments
Rhea-AI Summary
Integra LifeSciences (Nasdaq:IART) announced key leadership appointments in its commercial organization to support long-term growth and customer focus.
Robert T. Davis Jr. becomes EVP, Tissue Reconstruction and Distributed Technologies; Christopher Kilburn-Peterson is promoted to corporate VP and president, Tissue Reconstruction; Harvinder Singh becomes EVP and president, Specialty Surgery, while international leaders now report to chief commercial officer Mike McBreen.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Peers on Argus
IART showed a small positive move (+0.11%) while close peers were mixed, with several (e.g., SSII, INMD, BBNX) down and ESTA modestly up, suggesting a stock-specific reaction rather than a broad sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 15 | Conference presentation | Neutral | -1.7% | Announcement of presentation at 2026 Truist Securities MedTech Conference. |
| Jun 02 | Conference presentation | Neutral | +0.0% | Jefferies Global Healthcare Conference presentation by the CFO. |
| May 08 | Conference presentation | Neutral | +2.6% | BofA Securities 2026 Health Care Conference appearance by the CFO. |
| May 05 | Leadership transition | Positive | +24.1% | CEO transition to Stuart Essig and appointment of new CCO. |
| May 05 | Earnings release | Positive | +24.1% | Q1 2026 results with raised adjusted EPS guidance and reaffirmed revenue. |
Recent news, especially leadership and earnings updates, has generally aligned with positive share price reactions.
Regulatory & Risk Context
Short interest is at a moderate level, suggesting potential for elevated volatility and the possibility of sharper moves around catalysts.
The company has an effective Form S-3ASR shelf registration allowing future offerings of various securities, providing flexibility to raise capital as needed.
Market Pulse Summary
This announcement highlights refreshed commercial leadership, following earlier CEO and CCO changes and strong Q1 results with raised EPS guidance to $2.40–$2.50. Key risks center on execution of the new structure and its impact on growth.
AI-generated analysis. Not financial advice.
Leadership appointments reinforce company’s commitment to enhancing commercial execution and deepening customer engagement, while building leadership depth
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy.
Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Kilburn-Peterson has been promoted to corporate vice president and president for the Tissue Reconstruction division, reporting to Davis. He will be responsible for the division’s strategic direction, including commercial and portfolio priorities. Kilburn-Peterson most recently served as senior vice president and general manager of Acclarent, where he led the successful integration of the company’s ENT business.
Harvinder Singh, who previously led the international business, succeeds McBreen as executive vice president and president of the Specialty Surgery division, leading its commercial and portfolio strategy and business performance, and will report to him. With the international business aligned under McBreen’s commercial organization, the regional international leaders will now report directly to McBreen.
“These changes reflect our continued focus on commercial excellence, while developing internal talent and strengthening our leadership bench,” said Mike McBreen, executive vice president and chief commercial officer, Integra LifeSciences. “We are building strong management capabilities across the organization and positioning experienced leaders at the forefront of our market-facing activities. Bob, Chris, and Harvinder bring deep expertise, proven leadership, and a strong track record of execution that will help us deliver for customers and patients.”
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/daeb707f-cfa7-4617-beee-f00f28194901
https://www.globenewswire.com/NewsRoom/AttachmentNg/2a8e48ad-f79e-4610-ab74-287ac135fcbb
https://www.globenewswire.com/NewsRoom/AttachmentNg/1fb9e02a-375d-4a92-9208-657bee9ce339
